ASH 2022 Conference Coverage

 

Leukemia
10:42

ASH 2022 Conference Coverage

Results From the Phase 3 ALPINE Study: Zanubrutinib vs. Ibrutinib in R/R CLL & SLL

FEATURING Jennifer Brown
  • 203 views
  • April 14, 2023
05:06

ASH 2022 Conference Coverage

ASH 2022 Ponatinib & Blinatumomab for Patients With R/R Ph+ ALL or CML in Lymphoid Blast Phase: Subgroup Analysis From a Phase II Study

FEATURING Walid Macaron
  • 73 views
  • February 7, 2023
03:41

ASH 2022 Conference Coverage

ASH 2022: Venetoclax Combined With Cladribine, Idarubicin, Cytarabine (CLIA) as Induction Therapy in Pts With Newly Diagnosed AML and High-Risk MDS

FEATURING Gautam Borthakur
  • 177 views
  • January 28, 2023
  • 1
11:00

ASH 2022 Conference Coverage

ASH 2022 Updates and Highlights in CML

FEATURING Ehab Atallah
  • 126 views
  • January 27, 2023
14:41

ASH 2022 Conference Coverage

Clinical Implications of the QUAZAR AML-001 Trial: Oral AZA Maintenance With Focus on Patient Selection

FEATURING Pfeilstöcker Michael
  • 230 views
  • January 25, 2023
  • 1
19:04

ASH 2022 Conference Coverage

ASH 2022: Real-World Comparison of Time to Next Treatment for Patients With CLL Initiated on 1L Treatment With Ibrutinib vs. Acalabrutinib

FEATURING Ryan Jacobs
  • 132 views
  • January 13, 2023
  • 1
07:16

ASH 2022 Conference Coverage

CAPTIVATE Study Updates: CLL Treatment Outcomes After Undetectable MRD With 1L Ibrutinib + Venetoclax - Fixed Duration Treatment vs. Continued Ibrutinib With Up to 5 Years Median Follow-Up

FEATURING Constantine Tam
  • 149 views
  • January 11, 2023
  • 1
14:37

ASH 2022 Conference Coverage

ASH 2022 Results of the ASC4MORE Study: Asciminib Add-On to Imatinib, Continued Imatinib, or Switch to Nilotinib in Pts With CML-CP Not Achieving Deep Molecular Responses With ≥1 Year of Imatinib

FEATURING Giuseppe Saglio
  • 89 views
  • January 11, 2023
  • 1
11:30

ASH 2022 Conference Coverage

ASH 2022 Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated With HMA + Venetoclax Compared to CPX-351

FEATURING Akriti Jain
  • 380 views
  • January 11, 2023
  • 1
06:57

ASH 2022 Conference Coverage

ASH 2022 NX-2127-001, a First-in-Human Trial of NX-2127, a BTK-Targeted Protein Degrader, in Patients With R/R CLL and B-Cell Malignancies

FEATURING Alexey Danilov
  • 36 views
  • January 11, 2023
13:16

ASH 2022 Conference Coverage

Experts Discuss Key Updates in CLL

FEATURING Susan O'Brien, Catherine Coombs
  • 912 views
  • January 5, 2023
  • 7
10:41

ASH 2022 Conference Coverage

ASH 2022 Triplet Combination of Azacitidine, Venetoclax, and Gilteritinib for Pts With FLT3-Mutated AML: Updated Results From a Phase I/II Study

FEATURING Nicholas Short
  • 512 views
  • January 5, 2023
  • 3
06:22

ASH 2022 Conference Coverage

ASH 2022 The Addition of Inotuzumab Ozogamicin to Hyper-CVAD + Blinatumomab to Improve Outcomes in Pts With Newly Diagnosed B-ALL: Updated Results From a Phase II Study

FEATURING Nicholas Short
  • 149 views
  • January 5, 2023
07:38

ASH 2022 Conference Coverage

ASH 2022 Ponatinib & Blinatumomab for Pts With Newly Diagnosed Ph+ ALL: Subgroup Analysis From a Phase II Study

FEATURING Nicholas Short
  • 39 views
  • January 5, 2023
11:05

ASH 2022 Conference Coverage

ASH 2022 Preliminary Safety & Efficacy From the Phase 2 APEX Study of Bezuclastinib, a Novel, Highly Selective, Potent KIT D816V TKI, in Adults With Advanced Systemic Mastocytosis

FEATURING Daniel J. DeAngelo
  • 21 views
  • January 4, 2023
09:45

ASH 2022 Conference Coverage

ASH 2022 Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

FEATURING Kerry Rogers
  • 147 views
  • January 4, 2023
  • 1
11:10

ASH 2022 Conference Coverage

ASH 2022 Updated Phase 2b Results of Venetoclax With FLAG-IDA in R/R AML

FEATURING Marina Konopleva
  • 342 views
  • January 4, 2023
  • 1
08:14

ASH 2022 Conference Coverage

ASH 2022 Single vs. Double Induction With "7+3" Containing 60 vs. 90 mg Daunorubicin for Newly Diagnosed AML: Results From the Randomized Controlled SAL Dauno-Double Trial

FEATURING Christoph Röllig
  • 196 views
  • January 4, 2023
  • 2
07:48

ASH 2022 Conference Coverage

ASH 2022 Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase 1 SAL RELAX Trial

FEATURING Christoph Röllig
  • 100 views
  • January 4, 2023
  • 1
27:09

ASH 2022 Conference Coverage

ASH 2022: What Is Complete HLA Match in 2022?

FEATURING Stephen Spellman
  • 193 views
  • January 4, 2023
  • 2
11:12

ASH 2022 Conference Coverage

ASH 2022 Gene Edited Off-the-Shelf NK Cells for Treating Hematologic Disease

FEATURING Jeffrey Miller
  • 80 views
  • January 4, 2023
08:00

ASH 2022 Conference Coverage

ASH 2022 Phase III ASAP Trial Results: Sequential Conditioning & Immediate alloHCT Results in Similar OS and LFS Compared to Intensive Remission Induction Chemo Followed By alloHCT In R/R AML

FEATURING Johannes Schetelig
  • 70 views
  • January 3, 2023
15:43

ASH 2022 Conference Coverage

ASH 2022 UK NCRI AML19 Trial: FLAG-Ida With Gemtuzumab Ozogamicin Improves EFS in Younger Patients With Newly Diagnosed AML and Shows an OS Benefit in NPM1- & FLT3-Mutated Subgroups

FEATURING Nigel Russell
  • 87 views
  • December 28, 2022
  • 1
20:03

ASH 2022 Conference Coverage

ASH 2022: Post-Remission Outcomes in Patients With AML Are Similar Between HMA/Venetoclax Therapy & Intensive Chemo After Accounting for MRD Status

FEATURING Michael Hochman
  • 183 views
  • December 28, 2022
  • 3
09:54

ASH 2022 Conference Coverage

ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT With Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil

FEATURING Alex Hoover
  • 28 views
  • December 28, 2022
07:05

ASH 2022 Conference Coverage

ASH 2022: Lintuzumab-Ac225 in Combination With Intensive Chemo Yields High Response Rate and MRD Negativity in R/R AML With Adverse Features

FEATURING Sameem Abedin
  • 48 views
  • December 28, 2022
10:28

ASH 2022 Conference Coverage

ASH 2022 Phase 1 Study With the Novel Bcl-2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Pts With CLL/SLL: Preliminary Data

FEATURING Chan Cheah
  • 47 views
  • December 22, 2022
  • 2
06:20

ASH 2022 Conference Coverage

Consolidation With Allogeneic HCT Improved Survival Outcomes of Adults With R/R ALL Following Response to Memory-Enriched CD19 CAR T-Cells

FEATURING Ibrahim Aldoss
  • 73 views
  • December 22, 2022
  • 1
16:32

ASH 2022 Conference Coverage

ASH 2022 Phase 3 GLOW Study: Residual Disease Kinetics Among CLL Patients With High-Risk Factors Treated With 1L Fixed-Duration Ibr + Ven vs. Clb + Obi

FEATURING Carsten Utoft Niemann
  • 55 views
  • December 22, 2022
  • 1
04:07

ASH 2022 Conference Coverage

ASH 2022 Novel Combination of Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit MLL-r AML

FEATURING Suresh Balasubramanian
  • 137 views
  • December 22, 2022
  • 3
09:33

ASH 2022 Conference Coverage

ASH 2022 4-Year Follow-up Data on Combined Ibrutinib and Venetoclax for 1L Treatment of Pts With CLL

FEATURING Nitin Jain
  • 199 views
  • December 22, 2022
05:38

ASH 2022 Conference Coverage

ASH 2022 Preclinical In Vivo Activity of the Menin Inhibitor Ziftomenib (KO-539) in Pediatric KMT2A-Rearranged ALL

FEATURING Sarah Tasian
  • 68 views
  • December 22, 2022
  • 1
06:23

ASH 2022 Conference Coverage

ASH 2022 Comparing Venetoclax & Azacitidine to Conventional Induction Chemo for Newly Diagnosed Fit Adults With AML: Multi-Center Phase 2 Randomized Clinical Trial in Progress

FEATURING Amir Fathi
  • 800 views
  • December 22, 2022
  • 1
06:04

ASH 2022 Conference Coverage

ASH 2022 Final Analysis of the CLL2-GIVe Trial: Obinutuzumab, Ibrutinib, & Venetoclax in Untreated CLL With 17p Deletion/TP53 Mutation

FEATURING Stephan Stilgenbauer
  • 38 views
  • December 22, 2022
05:12

ASH 2022 Conference Coverage

ASH 2022 Asciminib as Initial Therapy for Patients With CML-CP: H. Jean Khoury Cure CML Consortium Study

FEATURING Ehab Atallah
  • 96 views
  • December 21, 2022
  • 1
09:42

ASH 2022 Conference Coverage

Transplant in AML With MRD: Proceed or Defer?

FEATURING Charles Craddock
  • 352 views
  • December 21, 2022
  • 2
15:42

ASH 2022 Conference Coverage

ASH 2022: Reduced Venetoclax Exposition to 7 Days of Azacitidine Is Efficient in Treatment-Naïve Pts With AML

FEATURING Christophe Willekens
  • 598 views
  • December 21, 2022
  • 1
07:37

ASH 2022 Conference Coverage

ASH 2022: More Than 10 Years Follow-Up of Frontline TKI Therapy in Patients With CML

FEATURING Fadi Haddad
  • 220 views
  • December 21, 2022
  • 1
07:41

ASH 2022 Conference Coverage

ASH 2022 Effectiveness of TKIs in Patients With CML-CP After Two or More Prior TKIs

FEATURING Daniela Žáčková
  • 104 views
  • December 21, 2022
  • 1
08:19

ASH 2022 Conference Coverage

ASH 2022 Results From the Phase 1/2 BRUIN Study: Safety & Tolerability of Pirtobrutinib Monotherapy in Patients With B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTKi

FEATURING Nirav Shah
  • 349 views
  • December 21, 2022
  • 3
08:12

ASH 2022 Conference Coverage

ASH 2022 Final Analysis Results From the InformCLL Registry: Real-World Outcomes With 1L Ibrutinib vs. Chemoimmunotherapy in Patients With CLL/SLL

FEATURING Nilanjan Ghosh
  • 37 views
  • December 21, 2022
11:38

ASH 2022 Conference Coverage

ASH 2022 ECOG-ACRIN-E1910 Randomized Phase III NCTN Trial: Blinatumomab for Newly Diagnosed BCR::ABL-Negative B-Lineage Adult ALL

FEATURING Mark Litzow
  • 117 views
  • December 19, 2022
  • 1
07:30

ASH 2022 Conference Coverage

ASH 2022 Efficacy & Safety of Ruxolitinib for Treatment of Symptomatic CMML: Results of a Multicenter Phase II Clinical Trial

FEATURING Eric Padron
  • 50 views
  • December 19, 2022
  • 1
08:00

ASH 2022 Conference Coverage

ASH 2022 Contemporary Guidelines for Diagnosis and Genomic Classification of ALL

FEATURING Ilaria Iacobucci
  • 55 views
  • December 19, 2022
08:02

ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil as the New Standard for GVHD Prophylaxis in Reduced Intensity Conditioning

FEATURING Shernan Holtan
  • 352 views
  • December 19, 2022
  • 1
04:55

ASH 2022 Conference Coverage

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamibarotene + Venetoclax & Azacitidine in RARA+ Newly Diagnosed AML Patients Ineligible for Standard Induction Chemo

FEATURING Eytan Stein
  • 167 views
  • December 16, 2022
11:52

ASH 2022 Conference Coverage

ASH 2022 Real-World OS and TTNT by 1L Therapy (BTKi and BCL2i) in Patients With CLL/SLL

FEATURING William Archibald, CK Wang
  • 119 views
  • December 16, 2022
05:33

ASH 2022 Conference Coverage

ASH 2022: Phase II Study of Inotuzumab Ozogamicin for the Treatment of MRD+ B-Cell ALL

FEATURING Jajastu Senapati
  • 62 views
  • December 16, 2022
10:39

ASH 2022 Conference Coverage

ASH 2022: Splicing Factor Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients With AML

FEATURING Jajastu Senapati
  • 34 views
  • December 16, 2022
07:43

ASH 2022 Conference Coverage

ASH 2022 The Menin Inhibitor Revumenib (SNDX-5613) Leads to Durable Responses in Pts With KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase 1 Study

FEATURING Ghayas Issa
  • 121 views
  • December 16, 2022
08:57

ASH 2022 Conference Coverage

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant AML and HR-MDS

FEATURING Jan Bewersdorf
  • 92 views
  • December 16, 2022
  • 1